^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MultiTAA T cell therapy
i
Other names: MultiTAA T cell therapy, MultiTAA-specific T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Baylor College of Medicine, Marker Therap
Drug class:
MAGE-A4 inhibitor, NY ESO 1 inhibitor, Survivin inhibitor, PRAME inhibitor, SSX2 inhibitor, Tumor-associated antigen inhibitor
Related drugs:
4ms
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)
P1, N=44, Recruiting, Baylor College of Medicine | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Apr 2024 --> Apr 2025
Trial completion date • Trial primary completion date
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
|
MultiTAA T cell therapy
4ms
TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (clinicaltrials.gov)
P2, N=12, Active, not recruiting, Baylor College of Medicine | Trial completion date: May 2024 --> May 2025
Trial completion date
|
MultiTAA T cell therapy
over1year
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)
P1, N=44, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2023 --> Apr 2024
Trial primary completion date
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane)
|
MultiTAA T cell therapy
over2years
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. (PubMed, Ther Adv Med Oncol)
This was associated with in vivo T-cell expansion, persistence, and antigen spreading. Future directions of this approach may include additional strategies to enhance the therapeutic benefit of multiTAA T cells in patients with BC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BIRC5 (Baculoviral IAP repeat containing 5) • CTAG1B (Cancer/testis antigen 1B) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
ER positive + PGR positive • PGR positive • EGFR positive • BIRC5 expression
|
MultiTAA T cell therapy
over2years
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov)
P1, N=44, Recruiting, Baylor College of Medicine | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Apr 2022 --> Apr 2023
Trial completion date • Trial primary completion date
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • WT1 (WT1 Transcription Factor) • CD33 (CD33 Molecule)
|
MultiTAA T cell therapy
Share via
